Navigation Links
Vasogen Provides Corporate Update
Date:1/6/2009

MISSISSAUGA, ON, Jan. 6 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today provided an update on corporate activities. Pursuant to a previously announced restructuring plan, Vasogen has been reviewing strategic alternatives for the purpose of enhancing shareholder value. This process has included screening, reviewing, and short-listing potential opportunities including the sale of the Company, a merger or acquisition, and exploring the monetization of certain tangible and intangible assets. The process has also included a review of the potential out-licensing of assets, asset divestiture, or liquidation of the Company. Vasogen also reported that during this process it has completed a number of initiatives to significantly reduce its base cash burn rate and conserve cash and completed its fiscal year end with over $8.5 million in cash resources.

"While the strategic review process has taken longer than hoped, we continue to be intensely focused on bringing this process to a close," commented Chris Waddick, President and CEO of Vasogen. "Based on our current status, we anticipate being in a position to provide a further update to shareholders before the end of January."

In October 2008, the NASDAQ Stock Market had suspended the enforcement of the rules requiring a minimum $1 closing price until January 20, 2009. Due to the "continued extraordinary market conditions" the NASDAQ has recently extended this suspension. Accordingly, the NASDAQ will not take action to delist any security, including Vasogen's shares, for a violation of the minimum bid price rule during the suspension, which now has been extended until April 20, 2009. Finally, effective December 31, 2008, Mr. Thomas Clarke has retired from Vasogen's Board of Directors. The Company wishes to thank Mr. Clarke for his services.

Certain statements in this documen
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Surrey have discovered how the receptors responsible for contractions ... The new study, published today in The FASEB ... turn regulates the cycle of all cells in the ... local biological clock and its control are weakened in ... bladder physiology and ageing. , While currently ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ophthalmic ... the interesting and challenging endeavors as the anatomy, ... impervious properties to the foreign substances. Ocular drug ... of self medication and minimal use of needles; ... weight drugs and provides specific targeting within the ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
(Date:8/21/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ® in the EU, today ... double-blind Phase 2a study of CCH for the ... The results showed that all three doses of ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at two upcoming investor conferences. The details are as ... Stanley Global Healthcare Unplugged Conference, Date: September 15, 2009, ... Grand Hyatt Hotel, New York, Speaker: Michael Narachi, President ...
... TAI,AN, China, Sept. ... Bulletin Board: CBPO) ("China Biologic," or the ... in the People,s,Republic of China ("PRC"), operating ... Products Co. Ltd. ("Taibang") and,Chongqing Dalin Biologic ...
... , , THE WOODLANDS, ... LXRX ), a biopharmaceutical company focused on discovering and developing ... Sands, M.D., Ph.D. , Lexicon,s president and chief executive officer, will ... Hyatt hotel in New York, New York on Tuesday, September 15, 2009 ...
Cached Biology Technology:China Biologic Products Appoints Director of Research and Development 2China Biologic Products Appoints Director of Research and Development 3Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:8/22/2014)... and clinical research and technological advances, the fight ... spanning multiple fronts. , Work happening in a ... new and more selective therapies for cancer. Researchers ... enzyme overexpressed in certain cancersand they have tested ... Chemistry professor Christopher Cairo and his team synthesized ...
(Date:8/22/2014)... of captive black rhino reproduction in Europe highlights ... breeding programmes. , Researchers from Chester Zoo, The ... carried out a six-year study which encompassed 90% ... Katie Edwards led the research as part of ... says: "Although some black rhinoceros breed well in ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Hormone analysis helps identify horny rhinos 2
... increases resulting from climate change in the Southwest will likely ... in 60 to 90 years, according to a new study ... research team used models of future climate, an analysis of ... and the fossil record to project the future distribution of ...
... on Osteoporosis & Osteoarthritis by investigators from the UK ... fractures in five major European countries totals 31 billion ... of the economic burden is shown to be related ... the fracture, while pharmacological prevention and treatment management constitutes ...
... Researchers with the Los Angeles County Department of Public ... pathogen, carbapenem-resistant Klebsiella pneumoniae (CRKP) among the patient population ... care hospitals across the county. These findings are ... to East Coast facilities and communities. These findings will ...
Cached Biology News:Uncertain future for Joshua trees projected with climate change 2Drug-resistant pathogen found in large numbers in LA County 2
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
Biology Products: